The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Age: 12 - 17 years
Gender: All
We've found 3 total result s for "Cardiomyopathy Hypertrophic".
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Age: 18 - 85 years
Gender: All
The purpose of this study is to collect long-term safety and tolerability data for aficamten.
Age: 18 - 85 years
Gender: All